• Safety of computed tomography (CTPA) to exclude pulmonary embolism (PE) in all patients is debated.
Summary. Background:
In patients with suspected pulmonary embolism (PE) classified as having a likely or high pretest clinical probability, the need to perform additional testing after a negative multidetector computed tomography pulmonary angiography (CTPA) finding remains a matter of debate. Objectives: To assess the safety of excluding PE by CTPA without additional imaging in patients with a likely pretest probability of PE. Patients/ Methods: We retrospectively analyzed patients included in two multicenter management outcome studies that assessed diagnostic algorithms for PE diagnosis. Results: Two thousand five hundred and twenty-two outpatients with suspected PE were available for analysis. Of these 2522 patients, 845 had a likely clinical probability as assessed by use of the simplified revised Geneva score. Of all of these patients, 314 had the diagnosis of PE excluded by a negative CTPA finding alone without additional testing, and were left without anticoagulant treatment and followed up for 3 months. Two patients presented with a venous thromboembolism (VTE) during follow-up. Therefore, the 3-month VTE risk in likely-probability patients after a negative CTPA finding alone was 2/314 (0.6%; 95% confidence interval [CI] 0.2-2.3%). Conclusions: In outpatients with suspected PE and a likely clinical probability as assessed by use of the simplified revised Geneva score, CTPA alone seems to be able to safely exclude PE, with a low 3-month VTE rate, which is similar
Introduction
Pulmonary embolism (PE) is a frequent and potentially fatal disease [1] . When suspected, it needs to be excluded or confirmed with the highest level of certainty possible.
With the rapid evolution of computed tomography pulmonary angiography (CTPA) technology, multidetector CTPA has emerged as the imaging technique of choice in PE diagnostic algorithms [2, 3] , and is now widely used as a stand-alone test to rule out PE. The safety of excluding PE on the basis of a normal CTPA finding alone without the need for lower-limb venous compression ultrasonography (CUS) has been studied on a large-scale basis in prospective management outcome trials, including a randomized non-inferiority diagnostic trial [4] . A systematic review and meta-analysis including > 3000 patients confirmed a high negative predictive value of CTPA for ruling out PE of 98.8% (95% confidence interval CI 98.2-99.2), and a very low subsequent 3-month venous thromboembolism (VTE) rate of 1.2% (95% CI 0.8-1.8%) [5] . It is of note that, in cases of negative CTPA findings in patients with a high pretest clinical probability, additional imaging was warranted/allowed in some of the clinical trials' protocols but was seldom performed, either in the trials or in daily practice.
Nevertheless, in spite of an overall decreased PE prevalence among all suspected outpatients, the PE prevalence remains high among patients classified as having a high clinical probability, ranging from 50% to 75% [6] . The question is thus whether the new generations of CTPA, with their increased sensitivity for PE, can offer sufficient negative predictive value (NPV) in this subgroup of patients with a high prevalence of the disease to safely exclude PE without additional testing.
Moores et al. recently performed a prospective noninterventional study to assess the safety of CTPA (64-row) to exclude PE in outpatients presenting to the emergency department of an academic center in Madrid with suspected PE and a high pretest clinical probability as assessed by the three-level Wells rule. Among 134 patients with a high clinical probability and a negative CTPA finding, seven were diagnosed with VTE either by another test at baseline (n = 5) or during a 3-month follow-up (n = 2), corresponding to an overall 'failure rate' of CTPA alone of 5.2% (95% CI 1.5-9.0%) [7] . The authors thus concluded that CTPA alone may not safely exclude PE in patients with a high clinical probability.
We aimed at reproducing this analysis and assessing whether CTPA alone would be safe for excluding PE in patients with a 'likely' clinical probability according to the simplified revised Geneva score.
Methods

Study design
We performed a retrospective analysis on data from two prospective management outcome studies including patients with suspected PE in which multidetector CTPA was part of the diagnostic strategy.
The first study (the CTEP4 study) was a multicenter randomized prospective management outcome study with a non-inferiority design comparing two strategies for the diagnosis of PE [4] . Both strategies were based on pretest clinical probability assessment with the revised Geneva score [8] , plasma D-dimer measurement with an ELISA assay (VIDAS; BioM erieux, Marcy-l'Etoile, France), and multidetector CTPA with or without lower-limb CUS. All consecutive outpatients admitted to the emergency department were included if they had a clinical suspicion of PE defined as an acute onset of new or worsening shortness of breath or chest pain without any other obvious etiology. Written informed consent was obtained from all patients. Patients with severe renal impairment, defined as a glomerular filtration rate of < 30 mL min À1 , were excluded from the study because of the potential need to perform CTPA with iodine contrast media. Therapeutic anticoagulation was introduced for patients with confirmed PE, and the rate of thromboembolic events was assessed at 3 months in all patients. The study was conducted between January 2005 and August 2006 in six different centers that serve as general and teaching hospitals in Belgium, France and Switzerland. The second study (the ADJUST-PE study) was a multicenter prospective management outcome study designed to prospectively validate the use of an age-adjusted D-dimer cutoff (defined as age 9 10 in patients aged ≥ 50 years) for the exclusion of PE, and to assess the incremental diagnostic yield of the age-adjusted D-dimer cutoff as compared with the conventional cutoff [9] . All consecutive outpatients presenting to the emergency department with suspected PE were included. The diagnostic strategy consisted of the sequential assessment of clinical probability by use of either the three-level simplified revised Geneva score or the two-level Wells score for PE [8, 10] , plasma D-dimer measurement with highly sensitive tests, and CTPA. Patients without PE were left without anticoagulant treatment. Patients with confirmed PE were prescribed therapeutic anticoagulation. Threemonth formal follow-up was performed, and the rate of thromboembolic events was assessed in all patients. The study was conducted in 19 centers in Belgium, France, the Netherlands and Switzerland between January 2010 and February 2013.
Patient population
We included patients from the CTEP4 and ADJUST-PE studies who had clinical probability assessment performed with the Geneva score. Therefore, patients in the ADJUST-PE study whose pretest probability was assessed with the Wells rule were not included in the present analysis. In order to include only patients who underwent CTPA alone, i.e. without CUS, we only included patients randomized to the 'CT without CUS' arm of the CTEP4 study. For the present analysis, we used the dichotomized version of the simplified revised Geneva score for our entire patient population [11] . Our study population thus consisted of outpatients with a likely PE probability as assessed with the simplified revised Geneva score in whom the diagnosis was excluded by CTPA alone. We also performed an additional analysis in patients classified as having a high clinical probability with the three-level simplified revised Geneva score. The different versions of the Geneva score are shown in Table 1 .
Imaging modalities
The CTPA protocol consisted of an assessment of the pulmonary arteries up to and including the subsegmental vessels. A clot was considered to be present if contrast material outlined an intraluminal defect or if a vessel was totally occluded by low-attenuation material. The number of detectors ranged from 16 to 64. The acquisition parameters were injection of a total volume of 100-120 mL of non-ionic contrast material (iodine concentration of 300-350 mg mL À1 ) with a power injector at 3-5 mL s -1 .
Imaging was performed 9-20 s after initiation of the injection based on bolus tracking. The technical parameters were: collimation 0.625 mm or 1.25 mm with a pitch of 0.9-1.75, 120 kV, and 115-260 mA s À1 and 0.6-0.8 s per gantry rotation, allowing reconstruction of images 0.625 mm or 1.25 mm in thickness at 0.6-1.0-mm intervals. CTPA findings were interpreted by staff radiologists as part of their daily clinical activity. CTPA findings were considered to be inconclusive if the CTPA was technically inadequate or if isolated subsegmental PE was described.
In the CTEP4 study, the protocol also required additional imaging in patients with a high clinical probability and negative CTPA findings. In both studies, further testing with ventilation/perfusion (V/Q) lung scan with or without pulmonary angiography was planned in cases of inconclusive CTPA findings.
Outcome analysis
The main outcome was the rate of objectively confirmed symptomatic VTE events in the 3-month follow-up period among patients left without anticoagulant treatment after the exclusion of PE by CTPA alone. This figure corresponds to the failure rate of a diagnostic strategy that would include CTPA as a stand-alone test in patients with PE-likely clinical probability.
In both the CTEP4 study and the ADJUST-PE study, the diagnosis of VTE during follow-up was established with the usual criteria on lower-limb CUS, V/Q scan, CTPA, or pulmonary angiography [4, 9] , and three independent experts blinded to the allocation group or to the D-dimer result adjudicated the outcome events. Deaths were adjudicated as related, possibly related or unrelated to PE. Death was judged to be related to PE in cases of autopsy confirmation or if it followed an objectively confirmed clinically severe PE. Sudden or unexpected death was considered to be possibly related to PE. Death from an obvious other cause was judged to be unrelated to PE.
It is of note that, in the original studies, patients were divided into three categories (low, intermediate, or high) of clinical probability according to the revised Geneva score in the CTPE4 study or according to the simplified revised Geneva score in the ADJUST-PE study. Less than 5% of patients were classified as having a high probability. In the present analysis, we used a dichotomized categorization (unlikely versus likely). There is thus an overlap between the likely patient group included in this analysis and the intermediate-score patient group in the original studies. This resulted in a significant number of patients with a likely score in whom PE had not been excluded by CTPA but by an intermediate clinical probability associated with a negative D-dimer test result. An additional analysis of outcomes limited to patients with a high clinical probability with the three-level Geneva score was also performed.
Data analysis
Analysis was performed with SPSS 23.0 (IBM Corp., Armonk, NY, USA).
Results
A total of 1819 patients were included in the CTEP4 study, of whom 903 were randomized to the diagnostic strategy, including clinical probability assessment, Ddimer measurement, and CTPA without lower-limb CUS. Two patients withdrew consent, leaving 901 patients in the intention-to-diagnose population. Overall, the PE prevalence was 21% (186/901). By use of the simplified revised Geneva score, 575 of 901 (64%) patients were classified as PE-unlikely and 326 of 901 (36%) as PElikely. PE was excluded in 218 of 326 (67%) PE-likely patients, 156 of whom were considered not to have PE on the basis of a negative CTPA finding alone.
For the present analysis, we considered the 156 patients with a PE-likely score in whom PE had been excluded by 
DVT, deep vein thrombosis; PE, pulmonary embolism.
a negative CTPA finding alone. Therapeutic anticoagulation was introduced for 14 patients for an indication other than VTE, and 11 patients died from a cause unrelated to PE, leaving 131 patients available for the analysis. None of these 131 patients experienced VTE during the 3-month follow-up (0/131). A total of 3324 patients were included in the ADJUST-PE study, of whom 1621 had clinical probability assessed with the simplified revised Geneva score. The overall PE prevalence was 19%. By use of the dichotomized version of the score, 1102 of 1621 (68%) patients were classified as PE-unlikely and 519 of 1621 (32%) as PE-likely. PE was excluded in 368 of 519 (71%) PE-likely patients, 227 of whom were considered not to have PE on the basis of a negative CTPA finding alone.
For the present analysis, we considered the 227 patients with a PE-likely score in whom PE had been excluded by a negative CTPA finding alone. Therapeutic anticoagulation was introduced for 32 patients for another indication, and 12 patients died from a cause unrelated to PE, leaving 183 patients available for the analysis. During follow-up, eight patients presented with clinically suspected VTE. After objective assessment, the diagnosis of VTE was excluded in six patients, was confirmed in one patient, and remained undetermined in one patient. As this study is related to the safety issues of a diagnostic strategy, we preferred, in our analysis, to consider this last patient as having experienced VTE. Therefore, the 3-month VTE rate was 2/183.
Altogether, of the overall 2522 patients available for the analysis, we could use the data from 845 outpatients with suspected PE and a PE-likely score according to the simplified revised Geneva score. Patients' characteristics are shown in Table 2 . The PE prevalence was 30.6% in this population. Of all of these patients, 314 had the diagnosis of PE excluded by a negative CTPA finding alone, i.e. without additional testing, and were left without anticoagulant treatment and followed up for 3 months. Only two patients experienced VTE during follow-up. The 3-month VTE rate after a negative CTPA finding alone was thus very low: 2/314 (0.6%; 95% CI 0.2-2.3%). The detailed flowchart of the study is shown in Fig. 1 .
In the additional analysis using the three-level simplified revised Geneva score, the numbers for patients classified as having a high clinical probability were as follows. Among the 845 patients with suspected PE and a PElikely score, 87 could be classified as having a high clinical probability. Of these, 39 of 87 had a confirmed PE, corresponding to a PE prevalence of 45%. Of the remaining 48 patients, 13 had PE excluded by a modality other than CTPA alone. Of the remaining 35 patients, seven were given anticoagulant treatment for another indication, and four died from a cause unrelated to VTE, leaving 24 patients with a high clinical probability in whom PE was ruled out by CTPA alone. None of these patients presented with a thromboembolic event during follow-up (0/24; 0.0%; 95% CI 0.0-13.8%).
Discussion
Our results suggest that multidetector CTPA used as a stand-alone test allows PE to be safely ruled out in patients with a PE-likely probability, without the need for additional testing, with a very low rate of subsequent VTE at 3 months (0.6%; 95% CI 0.2-2.3%). This is in contrast to the results from a single-center non-interventional study published by Moores et al., who showed a much higher rate of 3-month VTE (5.2%) among 134 patients with high pretest clinical probability after a negative CTPA finding. Their upper limit of the 95% CI was 9.0%, which is too high for exclusion of a potentially fatal disease, so their conclusion was that CTPA alone might not be safe for ruling out PE in patients with a high clinical probability.
What explains the major difference between our findings and the findings of Moores et al.? The setting was similar, consisting of consecutive outpatients presenting to emergency departments of an urban hospital with suspected PE. Mean age and other characteristics and comorbidities were comparable. Technical issues regarding CTPA cannot explain this difference either, as 64-row CTPA was used by Moores et al., whereas 16-64-row CTPA was used in the CTEP4 and ADJUST-PE studies. A major difference probably lies in the difference in PE prevalence between the two studies. In their study, Moores et al. selected patients with a high clinical probability by using a three-level Wells rule. Among their eligible 501 patients, 364 were diagnosed with PE by the CTPA. This represents a patient population with a 73% PE prevalence. In our study, patients with a PE-likely pretest probability according to a dichotomized simplified revised Geneva score were selected, and the PE prevalence was 30%. This major difference in prevalence could have an impact on the NPV of CTPA and explain the difference in outcomes. In our study, the analysis limited to the subset of patients classified as having a high clinical Table 2 Characteristics of pulmonary embolism (PE)-likely patients (n = 845) probability with a three-level score (PE prevalence of 45%) was reassuring, as none of these patients who had PE excluded by CTPA alone experienced a thromboembolic event during follow-up, a result that should nonetheless be interpreted with caution, owing to the small sample size. Moreover, the study by Moores et al. was an observational study, and 39 patients had CUS performed and 13 patients had a V/Q scan performed at baseline after the negative CTPA finding. Interestingly, five of the seven events in their study were actually diagnosed at baseline, and four of the patients had deep vein thrombosis (DVT). We do not know whether all of these DVTs were diagnosed in patients who also had concomitant suspicion of DVT, or whether they were found in patients without lower-limb symptoms. It is also impossible to infer what would have been the outcome of these patients if they had not had CUS performed and had been left untreated.
Previous management outcome studies have confirmed the safety of CTPA for excluding PE in diagnostic strategies using clinical probability assessment and D-dimer measurement to select patients in whom imaging is necessary [3, 4] . This was also shown in a meta-analysis by Mos et al. including > 3000 patients, which confirmed the safety of excluding PE by a normal CTPA-alone finding, with a 3-month VTE rate of 1.2% (95% CI 0.8-1.8%) [5] . It is of note that this meta-analysis included patients appropriately selected for the need for further CPTA, i.e. patients with a high or likely clinical probability or an elevated D-dimer level. However, the distinction between patients with a low-intermediate/unlikely clinical probability and a positive D-dimer finding, and patients with a high/likely probability, could not be made in terms of potential different outcomes, as none of the original studies reported separate results for these two groups of patients. Interestingly, the overall PE prevalence in patients selected for imaging included in this meta-analysis was 28%, and was therefore very similar to that found in our study.
In terms of accuracy, in the PIOPED II study, CTPA was assessed against a composite reference standard including V/Q lung scan and CUS with or without pulmonary angiography. The overall sensitivity of CTPA (4-16-row) for the diagnosis of PE was 83% (95% CI 76-92%), with an overall NPV of 95% (95% CI 92-96%). However, when patients with a high clinical probability were considered (three-level Wells rule), the NPV of CTPA was very low, at 60% (95% CI 32-83%), questioning the safety of CTPA for ruling out PE in patients with a high pretest probability.
Therefore, a significant discrepancy exists between the results of accuracy and outcome studies. This had been hypothesized as being possibly related to the limitations of CTPA in detecting very small thrombi that might not be clinically relevant if missed in terms of patient outcome [12, 13] . However, this hypothesis does not seem to be supported by more recent epidemiologic data, which, rather, suggest overdiagnosis and oversensitivity with regard to CTPA.
How should we integrate these findings into everyday clinical practice? The use of dichotomized rather than three-level clinical prediction rules seems to be becoming more generalized, probably mainly because a score cutoff with a binary classification is easier to remember than a score with several numbers and categories. Moreover, although the proportion of patients eligible for highly sensitive D-dimer testing to exclude PE is lower with dichotomized rules (65-75% of patients are usually classified as unlikely) [10, 14] than with a three-level score (> 90% of patients are classified as 'non-high', i.e. low and intermediate) [15] , the proportion of patients who will eventually need CTPA (i.e. with high/likely probability or elevated D-dimer levels) remains stable. Indeed, in clinical trials, two-thirds of the overall suspected patients need imaging regardless of the clinical probability assessment rule used (67-69%) [2] [3] [4] [5] . Furthermore, classifying a typical outpatient population (PE prevalence of 10-20%) with dichotomized rules allows the exclusion of PE with moderately sensitive D-dimer tests, which can be an important consideration in places where high-sensitivity D-dimer measurement is not available [6] .
Therefore, it seems difficult to change worldwide practice and promote the need to use a three-level score in all patients with suspected PE, with the only aim being the selection of high-probability patients who will need further testing in cases of negative CTPA findings. Clinical judgement will thus, as usual, be central to the decision on whether to perform additional testing in an individual patient.
Previously, when less sensitive single-detector CTPA was used, adding CUS to CTPA had been shown to increase the sensitivity of diagnostic strategies and to allow PE to be safely ruled out in suspected patients [16, 17] . However, as mentioned above, in outcome studies, routine CUS was not shown to be useful when multidetector CTPA was used [4] . Searching for proximal DVT by adding computed tomography venography (CTV) to multidetector CTPA in the PIOPED II study increased the sensitivity, but the impact on the NPV of the combination was still insufficient in high-probability patients (82% with CTPA + CTV versus 60% with CTPA alone) [18] . The addition of CUS to CTPA in patients with a high clinical probability could thus be a strategy to consider. The need to perform additional thoracic imaging still remains a matter of debate.
Our study has some limitations. Although all items of the Geneva score were collected prospectively, the dichotomized Geneva score was retrospectively calculated. Also, the analysis limited to the high-probability patients with the three-level score is limited by the small sample size, resulting in a wide CI (0/24; 95% CI 0.0-13.8%).
Our study has also many strengths, as data were obtained from two prospective management outcome studies, in which the PE diagnosis strategy was well defined, and consecutive outpatients were included. Also, a formal 3-month follow-up was performed in all patients.
In conclusion, our data are reassuring and suggest that, in outpatients with a likely clinical probability, the use of CTPA as the only exclusion diagnostic test safely rules out PE, the 3-month thromboembolic rate being very low and in line with international recommendations regarding the safety of diagnostic strategies for PE.
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